You're using an outdated browser. This website will not display correctly and some features will not work.
Learn more about the browsers we support for a faster and safer online experience.

Important: This version of the e-Laws website will be upgraded to a new version in the coming weeks.
You can try the beta version of the new e-Laws at ontario.ca/laws-beta.

 

ontario regulation 54/06

made under the

drug interchangeability and dispensing fee act

Made: March 1, 2006
Filed: March 3, 2006
Published on e-Laws: March 6, 2006
Printed in The Ontario Gazette: March 18, 2006

Amending Reg. 935 of R.R.O. 1990

(General)

1. (1) The definition of “Formulary” in subsection 1 (1) of  Regulation 935 of the Revised Regulations of Ontario, 1990 is revoked and the following substituted:

“Formulary” means the Ministry of Health and Long-Term Care publication titled “Drug Benefit Formulary/Comparative Drug Index” (No. 39) dated September 27, 2005, and includes the following amendments to the publication:

1. Amendments dated January 12, 2006.

2. Amendments dated April 19, 2006;

(2) Subsection 1 (1.1) of the Regulation is revoked. 

(3) Section 1 of the Regulation is amended by adding the following subsection:

(1.3) For the purposes of this Regulation, item 231 of Part III of the Formulary shall be read as follows:

 

231

2.5 mg Tab

 

 

4.9500

 

02231384

Femara (Letrozole)

NOV

4.9500

 

Reason for Use Code

Clinical Criteria

 

365

For the treatment of metastatic breast cancer in hormone receptor positive postmenopausal women. LU Authorization Period: Indefinite.

 

403

For the treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. LU Authorization Period: 5 Years.

2. This Regulation comes into force on April 19, 2006.